Matched Paired Primary and Recurrent Meningiomas Points to Cell-Death Program Contributions to Genomic and Epigenomic Instability along Tumor Progression.

Meningioma (MN) is an important cause of disability, and predictive tools for estimating the risk of recurrence are still scarce. The need for objective and cost-effective techniques addressed to this purpose is well known. In this study, we present methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) as a friendly method for deepening the understanding of the mechanisms underlying meningioma progression. A large follow-up allowed us to obtain 50 samples, which included the primary tumor of 20 patients in which half of them are suffering one recurrence and the other half are suffering more than one. We histologically characterized the samples and performed MS-MLPA assays validated by FISH to assess their copy number alterations (CNA) and epigenetic status. Interestingly, we determined the increase in tumor instability with higher values of CNA during the progression accompanied by an increase in epigenetic damage. We also found a loss of HIC1 and the hypermethylation of CDKN2B and PTEN as independent prognostic markers. Comparison between grade 1 and higher primary MN's self-evolution pointed to a central role of GSTP1 in the first stages of the disease. Finally, a high rate of alterations in genes that are related to apoptosis and autophagy, such as DAPK1, PARK2, BCL2, FHIT, or VHL, underlines an important influence on cell-death programs through different pathways.

Desmoplastic infantile astrocytoma with atypical phenotype, PTEN homozygous deletion and BRAF V600E mutation.

Desmoplastic infantile astrocytoma (DIA) is rare, cystic and solid tumor of infants usually found in superficial cerebral hemispheres. Although DIA is usually benign, uncommon cases bearing malignant histological and aggressive clinical features have been described in the literature. We report a newborn patient who was diagnosed with a DIA and died postresection. Pathologic examination revealed that the main part of the tumor had benign features, but the internal region showed areas with a more aggressive appearance, with higher-proliferative cells, anaplastic GFAP positive cells with cellular polymorphism, necrosis foci, vascular hyperplasia with endothelial proliferation and microtrombosis. Genetic study, performed in both regions of the tumor, showed a BRAF V600E mutation and a homozygous deletion in PTEN, without changes in other relevant genes like EGFR, CDKN2A, TP53, NFKBIA, CDK4, MDM2 and PDGFRA. Although PTEN homozygous deletions are described in gliomas, the present case constitutes the first report of a PTEN mutation in a DIA, and this genetic feature may be related to the malignant behavior of a usually benign tumor. These genetic findings may point at the need of further and deeper genetic characterization of DIAs, in order to better understand the biology of this tumor and to obtain new prognostic approaches, a better clinical management and targeted therapies, especially in malignant cases of DIA.

El Psicólogo en el Primer Nivel de Atención de Salud: desafíos para Uruguay

Resumen: En Uruguay cada vez más se reconoce la importancia del profesional psicólogo en el Primer Nivel de Atención (PNA). En la actualidad se transita una oportunidad única ya que el Plan Nacional de Salud Mental 2020-2027 (PNSM) recientemente aprobado, plantea su incorporación en forma expresa. El presente artículo analiza el rol del psicólogo en el PNA, realiza un recorrido internacional seleccionando algunos países en los que se muestran diversos modos de incorporación de los psicólogos en este rol. Se aborda a continuación cuál es la situación del psicólogo en el PNA en Uruguay. Por último, se plantean algunos de los desafíos que implica renovar el trabajo tradicional del psicólogo clínico, e incorporar las competencias y prácticas profesionales características del PNA.

Abstract: In Uruguay, the importance of the professional psychologist in the First Level of Health Care (PNA) is increasingly recognized, and currently there is a unique opportunity since the recently approved National Mental Health Plan 2020-2027 (PNSM), raises its incorporation expressly. This article analyzes the role of the psychologist in PNA, makes an international review selecting some countries in which the various ways in which psychologists have been incorporated into this role are shown. The situation of the psychologist in the PNA in Uruguay is discussed below. Finally, some of the challenges faced are raised, which implies renewing the traditional role of the clinical psychologist, and incorporating the competencies and professional practices characteristic of the PNA.

Resumo: No Uruguai, a importância do psicólogo profissional no Primeiro Nível de Atenção de Saúde (PNA) é cada vez mais reconhecida, e atualmente existe uma oportunidade única desde o recém-aprovado Plano Nacional de Saúde Mental 2020-2027 (PNSM), levanta expressamente a sua incorporação. Este artigo faz análise do papel do psicólogo na PNA, faz uma revisão internacional selecionando alguns países nos quais são mostradas as diversas formas pelas quais os psicólogos foram incorporados a essa função. A seguir se discute a situação do psicólogo na PNA do Uruguai. Por fim, são apresentados alguns dos desafios que implica a renovação do papel tradicional do psicólogo clínico e incorporar as competências e práticas profissionais próprias da PNA.

Whole-exome sequencing, EGFR amplification and infiltration patterns in human glioblastoma.

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. This cancer shows rapid, highly infiltrative growth, that invades individually or in small groups the surrounding tissue. The aggressive tumor biology of GBM has devastating consequences with a median survival of 15 months. GBM often has Epidermal Growth Factor Receptor (EGFR) abnormalities. Despite recent advances in the study of GBM tumor biology, it is unclear whether mutations in GBM are related to EGFR amplification and relevant phenotypes like tumor infiltration. This study aimed to perform whole-exome sequencing analysis in 30 human GBM samples for identifying mutational portraits associated with EGFR amplification and infiltrative patterns. Our results show that EGFR-amplified tumors have overall higher mutation rates than EGFR-no-amplified. Six genes out of 2029 candidate genes show mutations associated with EGFR amplification status. Mutations in these genes for GBM are novel, not previously reported in GBM, and with little presence in the TCGA database. GPR179, USP48, and BLK show mutation only in EGFR-amplified cases, and all the affected cases exhibit diffuse infiltrative patterns. On the other hand, mutations in ADGB, EHHADH, and PTPN13, were present only in the EGFR-no-amplified group with a more diverse infiltrative phenotype. Overall, our work identified different mutational portraits of GBM related to well-established features like EGFR amplification and tumor infiltration.

Identification of New Genetic Clusters in Glioblastoma Multiforme: EGFR Status and ADD3 Losses Influence Prognosis.

Glioblastoma multiforme (GB) is one of the most aggressive tumors. Despite continuous efforts to improve its clinical management, there is still no strategy to avoid a rapid and fatal outcome. EGFR amplification is the most characteristic alteration of these tumors. Although effective therapy against it has not yet been found in GB, it may be central to classifying patients. We investigated somatic-copy number alterations (SCNA) by multiplex ligation-dependent probe amplification in a series of 137 GB, together with the detection of EGFRvIII and FISH analysis for EGFR amplification. Publicly available data from 604 patients were used as a validation cohort. We found statistical associations between EGFR amplification and/or EGFRvIII, and SCNA in CDKN2A, MSH6, MTAP and ADD3. Interestingly, we found that both EGFRvIII and losses on ADD3 were independent markers of bad prognosis (p = 0.028 and 0.014, respectively). Finally, we got an unsupervised hierarchical classification that differentiated three clusters of patients based on their genetic alterations. It offered a landscape of EGFR co-alterations that may improve the comprehension of the mechanisms underlying GB aggressiveness. Our findings can help in defining different genetic profiles, which is necessary to develop new and different approaches in the management of our patients.

Identification of a Novel BRCA1 Alteration in Recurrent Melanocytoma Resulting in Increased Proliferation.

Primary meningeal melanocytomas are rare tumors of the central nervous system. Although they are considered benign neoplasms, some reports describe recurrent rates up to 45%. Little is known about their genetic and epigenetic landscape because of their infrequency. Even less has been described about markers with prognostic value. Here we describe a patient who developed a primary meningeal melanocytoma, suffered 3 recurrences in a period of 6 years and died of the tumor. The genetic and epigenetic changes explored confirmed GNAQ mutation as an initiating event. We found an epigenetic alteration of GSTP1, a feature that has recently been described in meningiomas, from the beginning of the disease. In addition, there was loss of heterozygosity in BRCA1 beginning in the second recurrence that was linked to an increase in the proliferation index; this suggested a progression pathway similar to the one described in uveal melanomas. These findings underscore the necessity of further research focused on these tumors.

The Status of EGFR Modulates the Effect of miRNA-200c on ZEB1 Expression and Cell Migration in Glioblastoma Cells.

Migration of glioblastoma cells into surrounding tissue is one of the main features that makes this tumor incurable. We evaluated whole-genome miRNA expression profiling associated with different EGFR amplification patterns in 30 cases of primary glioblastoma. From the 64 miRNAs that showed differential expression between tumors with a high level of EGFR amplification and tumors without EGFR amplification, 40% were related with cell migration, being miR-200c the most differentially expressed between these two groups. We investigated the effect of miR-200c on ZEB1 expression and cell migration in an in vitro transfection model with a miR-200c mimic, a miR-200c inhibitor and siRNA targeting EGFR in three short-term cultures with different levels of EGFR amplification obtained from resected glioblastomas. The cell culture with the highest EGFR amplification level presented the lowest miR-200c expression and the status of EGFR modulated the effect of miR-200c on ZEB1 expression. Silencing EGFR led to miR-200c upregulation and ZEB1 downregulation in transfected cultures, except in the presence of high levels of EGFR. Likewise, miR-200c upregulation decreased ZEB1 expression and inhibited cell migration, especially when EGFR was not amplified. Our results suggest that modulating miR-200c may serve as a novel therapeutic approach for glioblastoma depending on EGFR status.

Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide.

Glioblastoma multiforme (GBM) is the most aggressive human brain tumor, and GBM stem cells (GSC) may be responsible for its recurrence and therapeutic resistance. Toll-like receptors (TLRs), which recognize multiple ligands (endogenous and pathogen-associated) and trigger the immune response of mature immune cells, are also expressed by hematopoietic stem and progenitor cells, where their activation results in the differentiation of these cells into myeloid cells. Since TLR expression has been recently described in neural cells, including neural stem cells, we studied TLR expression by GSCs and the effect of stimulation by TLR ligands on promoting GSC differentiation into mature GBM cells. First, our results showed heterogeneous TLR expression by GBM cells from human tumors and, for the first time, by human GSCs defined by their CD133+ and CD44+ phenotypes. Next, the effect of TLR ligands was studied in in vitro cell cultures of neurospheres and CD44+ cells obtained from two GBM cell lines (U-87 and U-118). The expression of GSC markers diminished in the presence of Pam3CSK4 or LPS (TLR2 and TLR4 ligands, respectively), thus indicating TLR-dependent differentiation. Interestingly, simultaneous treatment with Pam3CSK4 plus temozolomide (TMZ), the reference drug in GBM treatment, significantly increased cell death compared to the effect of the ligand alone, which showed no toxicity, or TMZ alone. These results suggest a synergistic effect between Pam3CSK4 and TMZ based on the induction of TLR-dependent GSC differentiation towards mature GBM cells, which exhibited increased sensitivity to chemotherapy, and provide new perspectives in GBM therapy.

Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.

Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system. With no effective therapy, the prognosis for patients is terrible poor. It is highly heterogeneous and EGFR amplification is its most frequent molecular alteration. In this light, we aimed to examine the genetic heterogeneity of GBM and to correlate it with the clinical characteristics of the patients. For that purpose, we analyzed the status of EGFR and the somatic copy number alterations (CNAs) of a set of tumor suppressor genes and oncogenes. Thus, we found GBMs with high level of EGFR amplification, low level and with no EGFR amplification. Highly amplified tumors showed histological features of aggressiveness. Interestingly, accumulation of CNAs, as a measure of tumor mutational burden, was frequent and significantly associated to shortened survival. EGFR-amplified GBMs displayed both a higher number of concrete CNAs and a higher global tumor mutational burden than their no EGFR-amplified counterparts. In addition to genetic changes previously described in GBM, we found PARK2 and LARGE1 CNAs associated to EGFR amplification. The set of genes analyzed allowed us to explore relevant signaling pathways on GBM. Both PARK2 and LARGE1 are related to receptor tyrosine kinase/PI3K/PTEN/AKT/mTOR-signaling pathway. Finally, we found an association between the molecular pathways altered, EGFR amplification and a poor outcome. Our results underline the potential interest of categorizing GBM according to their EGFR amplification level and the usefulness of assessing the tumor mutational burden. These approaches would open new knowledge possibilities related to GBM biology and therapy.

Characterization of a new glioblastoma cell line, GB-val4, with unusual TP53 mutation.

A novel cell line derived from a human glioblastoma (GB), named GB-val4, has been established and characterized. GB-val4 cells were hyperdiploid, with many numerical and structural chromosomal rearrangements. The cell line did not show mutations in IDH1/IDH2 genes or EGFR amplification, but it presented two missense mutations in TP53, which imply a very low p53 protein activity within the cell line. Cells also had gain of TP73 copies, hypermethylation of APC, CASP8 and RASSF1, increased expression of ARF1, CDH1 and NF-κB and decreased expression of CDKN2A. Tumorigenity was demonstrated by transplant of GB-val4 cells into athymic nude mice, where solid tumors were grown. Interestingly, a high percentage of GB-val4 cells presented expression of GSC markers CD133 or CD44. These GSC markers were increased in neurosphere cultures, which better mimic solid tumor conditions and maintain the genetic features of the tumor cells. In this study, we aimed to define the characteristics of this novel cell line and its applications in human cancer research. With its genetic features and a poor p53 activity, GB-val4 cells resemble GB tumors. Moreover, the important presence of GSCs in adherent cultures and especially in neurosphere cultures makes GB-val4 an attractive tool to study cancer stem cells, deepen in the knowledge the molecular pathways of GB and develop new therapeutic strategies for patients with these tumors.

Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.

Meningiomas are the most frequent primary brain tumor. Usually, they are curable by surgery, but even after seemingly complete resection, some low-grade lesions recur. Despite recent improvements, signatures having prognostic value in grade I tumors remain poorly characterized. The frequency and delicate location of these tumors suggest that the risk of recurrence might be more accurately predicted. Herein, we show an easy way to evaluate the methylation status of meningiomas and its correlation with the prognosis of the disease. A series of 120 meningiomas, including primary tumors and recurrences, were analyzed histopathologically, and 24 tumor suppressor genes (TSGs) were studied by methylation-specific multiple ligation probe amplification. Long-term follow-up was conducted to classify patients with grade I primary tumors according to their outcomes. We found that hypermethylation in at least one TSG is frequent. The number of hypermethylated TSG per case was significantly higher in recurrences than in primary tumors and in primary benign meningiomas that recurred than in tumors from patients who showed no evidence of disease during follow-up. Finally, hypermethylation in RASSF1A, MLH1, and CDKN2B was an independent prognostic factor associated with the time to recurrence of these benign tumors that were biologically aggressive. To our knowledge, this is one of the widest studies of primary grade I tumors of patients who developed a tumor recurrence. The frequency of epigenetic changes suggests that hypermethylation is an early event in meningiomas, whereas the accumulation of epigenetic changes is related to greater biological aggressiveness and may be a signature of potential clinical relevance.

Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.

PURPOSE: Glioblastoma (GB) is the most frequent and most malignant primary brain tumor in adults. Previously, it has been found that both genetic and epigenetic factors may play critical roles in its etiology and prognosis. In addition, it has been found that the epidermal growth factor receptor gene (EGFR) is frequently over-expressed and amplified in primary GBs. Here, we assessed the promoter methylation status of 10 genes relevant to GB and explored associations between these findings and the EGFR gene amplification status. METHODS: Tumor samples were obtained from 36 patients with primary GBs. In addition, 6 control specimens were included from patients who were operated for diseases other than brain tumors. The amplification status of the EGFR gene, and its deletion mutant EGFRvIII, were evaluated using FISH and MLPA, respectively. The IDH1/2 gene mutation status was verified using Sanger sequencing. A commercial DNA methylation kit was used to assess the promoter methylation status of 10 pre-selected genes. Metabolic profiles were measured using HR-MAS NMR spectroscopy. The EGFR and ARF1 mRNA expression levels were quantified using qRT-PCR. RESULTS: Of the 10 genes analyzed, we found that only ARF1 promoter hypermethylation was significantly associated with EGFR gene amplification. ARF1 is a GTPase that is involved in vesicle trafficking and the Golgi apparatus. Subsequent tumor metabolism measurements revealed a positive association between EGFR amplification and different membrane precursors and methyl-donor metabolites. Finally, we found that EGFR gene amplifications were associated with distinct tumor infiltration patterns, thus representing a putative novel functional association between EGFR gene amplification and ARF1 gene promoter methylation in GB. CONCLUSIONS: The results reported here provide a basis for a new hypotheses connecting EGFR gene amplification in GB cells with ARF1 gene promoter methylation, vesicle trafficking, membrane turnover and tumor metabolism. The mechanism(s) underlying these connections and their functional consequences remain to be established.

La simpaticotomía videtoracoscópica en el tratamiento de la hipehidrosis palmar / Videothoracoscopic simpathicotomy on the treatment of palmar hyperidrosis

Introducción: la simpaticotomía videotoracoscópica es actualmente la técnica quirúrgica de elección en el tratamiento de la hiperhidrosis esencial o primaria. Sus ventajas relacionadas con su sencillez, menor posibilidades de complicaciones transoperatorias, un tiempo quirúrgico notablemente más corto y consecuentemente menor exposición a los agentes anestésicos, mejor relación riesgo/beneficio, mejor recuperación y la disminución de los efectos secundarios como el sudor compensatorio y el alto nivel de satisfacción de los pacientes, justifican su realización. Objetivo: analizar los resultados de la generalización de la simpaticotomía T3-T4 en el tratamiento de la hiperhidrosis palmar. Método: estudio de corte transversal, observacional y descriptivo de los pacientes intervenidos por videotoracoscopia, en el Centro Nacional de Cirugía de Mínimo Acceso con el diagnóstico de hiperhidrosis primaria palmar; a los cuales se les realizó simpaticotomía videotoracoscópica desde enero de 2011 hasta diciembre del 2015. En la evaluación de los pacientes se tienen en cuenta las variables aceptadas internacionalmente: curación, efectos secundarios, complicaciones y la mejoría psíquica dada por el nivel de satisfacción de los pacientes. Resultados: se logró un 97,69 por ciento de curación de la enfermedad. La sudoración compensatoria se presentó en 48,1 por ciento de los pacientes y el nivel de satisfacción fue de 97 por ciento, logrando una mejoría evidente del estado psicológico de los mismos. Conclusiones: la simpaticotomía videotoracoscópica T3-T4 es efectiva en el tratamiento de los pacientes afectos de hiperhidrosis palmar(AU)

Introduction: Videothoracoscopic sympathicotomy is currently the surgical technique of choice in the treatment of primary or essential hyperhidrosis. Its advantages related to its simplicity, fewer possibilities of transoperative complications, remarkably shorter surgical time and consequently less exposure to anesthetic agents, better risk / benefit ratio, better recovery, limited side effects such as compensatory sweat and high level of patient satisfaction support the performance of this procedure. Objective: To analyze the results of the generalization of the T3-T4 sympathicotomy in the treatment of palmar hyperhidrosis. Method: A cross-sectional, observational and descriptive study of patients with diagnosis of palmar primary hyperhidrosis, who underwent videothoracoscopic sympathicotomy at the National Center for Minimal Access Surgery from January 2011 to December 2015. The patient assessment took into account internationally accepted variables such as healing, side effects, complications and psychic improvement according to the level of satisfaction of the patients. Results: Recovery from disease reached 97.69 percent, compensatory sweating occurred in 48.1 percent of patients and the level of satisfaction was 97 percent, thus achieving clear improvement of the psychological state of patients.. Conclusions: Videothoracoscopic sympathicotomy T3-T4 is effective in the treatment of patients with palmar hyperhidrosis(AU)

La simpaticotomía videtoracoscópica en el tratamiento de la hipehidrosis palmar / Videothoracoscopic simpathicotomy on the treatment of palmar hyperidrosis

Introducción: la simpaticotomía videotoracoscópica es actualmente la técnica quirúrgica de elección en el tratamiento de la hiperhidrosis esencial o primaria. Sus ventajas relacionadas con su sencillez, menor posibilidades de complicaciones transoperatorias, un tiempo quirúrgico notablemente más corto y consecuentemente menor exposición a los agentes anestésicos, mejor relación riesgo/beneficio, mejor recuperación y la disminución de los efectos secundarios como el sudor compensatorio y el alto nivel de satisfacción de los pacientes, justifican su realización. Objetivo: analizar los resultados de la generalización de la simpaticotomía T3-T4 en el tratamiento de la hiperhidrosis palmar. Método: estudio de corte transversal, observacional y descriptivo de los pacientes intervenidos por videotoracoscopia, en el Centro Nacional de Cirugía de Mínimo Acceso con el diagnóstico de hiperhidrosis primaria palmar; a los cuales se les realizó simpaticotomía videotoracoscópica desde enero de 2011 hasta diciembre del 2015. En la evaluación de los pacientes se tienen en cuenta las variables aceptadas internacionalmente: curación, efectos secundarios, complicaciones y la mejoría psíquica dada por el nivel de satisfacción de los pacientes. Resultados: se logró un 97,69 por ciento de curación de la enfermedad. La sudoración compensatoria se presentó en 48,1 por ciento de los pacientes y el nivel de satisfacción fue de 97 por ciento, logrando una mejoría evidente del estado psicológico de los mismos. Conclusiones: la simpaticotomía videotoracoscópica T3-T4 es efectiva en el tratamiento de los pacientes afectos de hiperhidrosis palmar(AU)

Introduction: Videothoracoscopic sympathicotomy is currently the surgical technique of choice in the treatment of primary or essential hyperhidrosis. Its advantages related to its simplicity, fewer possibilities of transoperative complications, remarkably shorter surgical time and consequently less exposure to anesthetic agents, better risk / benefit ratio, better recovery, limited side effects such as compensatory sweat and high level of patient satisfaction support the performance of this procedure. Objective: To analyze the results of the generalization of the T3-T4 sympathicotomy in the treatment of palmar hyperhidrosis.Method: A cross-sectional, observational and descriptive study of patients with diagnosis of palmar primary hyperhidrosis, who underwent videothoracoscopic sympathicotomy at the National Center for Minimal Access Surgery from January 2011 to December 2015. The patient assessment took into account internationally accepted variables such as healing, side effects, complications and psychic improvement according to the level of satisfaction of the patients. Results: Recovery from disease reached 97.69 percent, compensatory sweating occurred in 48.1 percent of patients and the level of satisfaction was 97 percent, thus achieving clear improvement of the psychological state of patients. Conclusions: Videothoracoscopic sympathicotomy T3-T4 is effective in the treatment of patients with palmar hyperhidrosis(AU)

Correlation between EGFR amplification and the expression of microRNA-200c in primary glioblastoma multiforme.

Extensive infiltration of the surrounding healthy brain tissue is a critical feature in glioblastoma. Several miRNAs have been related to gliomagenesis, some of them related with the EGFR pathway. We have evaluated whole-genome miRNA expression profiling associated with different EGFR amplification patterns, studied by fluorescence in situ hybridization in tissue microarrays, of 30 cases of primary glioblastoma multiforme, whose clinicopathological and immunohistochemical features have also been analyzed. MicroRNA-200c showed a very significant difference between tumors having or not EGFR amplification. This microRNA plays an important role in epithelial-mesenchymal transition, but its implication in the behavior of glioblastoma is largely unknown. With respect to EGFR status our cases were categorized into three groups: high level EGFR amplification, low level EGFR amplification, and no EGFR amplification. Our results showed that microRNA-200c and E-cadherin expression are down-regulated, while ZEB1 is up-regulated, when tumors showed a high level of EGFR amplification. Conversely, ZEB1 mRNA expression levels were significantly lower in the group of tumors without EGFR amplification. Tumors with a low level of EGFR amplification showed ZEB1 expression levels comparable to those detected in the group with a high level of amplification. In this study we provide what is to our knowledge the first report of association between microRNA-200c and EGFR amplification in glioblastomas.

Genetic changes with prognostic value in histologically benign meningiomas.

Meningiomas add up to 25% of intracranial tumors. Although the majority is considered histologically benign, the prediction of their potential aggressiveness is still unclear. We studied the histopathology and aberrations of chromosomes 1p, 14, and 22 by FISH (fluorescence in situ hybridization) in histologically benign meningiomas of 70 patients for the purpose of defining the prognostic value of these alterations in tumoral progression and the risk of recurrence. According to the WHO histopathological criteria, the study set comprised 53 benign, 11 atypical, and 6 anaplastic meningiomas. In benign meningiomas, 25% of the cases displayed a normal karyotype, isolated monosomy 22 (36%), monosomy 22 + 1p deletion (14%), 1p deletion (10%), monosomy 22 + 14q deletion (5%), monosomy 22 + 1p deletion + 14q deletion (5%), or other alterations (5%). Grade II meningiomas presented losses in chromosome 14 in most of the cases (67%), and Grade III meningiomas showed alterations in chromosome 14 in all patients. We observed an overall relapse rate of 31%: recurrence was observed in 19% of Grade I meningiomas, 64% of Grade II, and 83% of Grade III. 9 out of 10 recurrent cases revealed abnormalities in chromosomes 1 and 14, which was a notably higher incidence compared to the series of tumors without relapse. Thus, benign meningiomas with cytogenetic alterations in chromosomes 1p and 14 may be more closely related to atypical meningiomas than benign meningiomas without these alterations, especially in terms of recurrence risk.